Targeted Strategies for Today's Evolving Markets

MissionIR Blog

CytRx (CYTR) Presents at Rodman & Renshaw Conference

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. CytRx is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated, under a special protocol assessment, a pivotal phase III global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. For more information, visit the company’s website at www.cytrx.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.